Martín de la Fuente L - Search Results

1

MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer.

Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I. Bååth M, et al. Among authors: martin de la fuente l. Genes (Basel). 2021 May 14;12(5):742. doi: 10.3390/genes12050742. Genes (Basel). 2021. PMID: 34069138 Free PMC article.

2

Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.

Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I. Martín de la Fuente L, et al. Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394. Int J Gynecol Pathol. 2018. PMID: 28481779 Free PMC article.

3

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.

Martin de la Fuente L, Westbom-Fremer S, Arildsen NS, Hartman L, Malander S, Kannisto P, Måsbäck A, Hedenfalk I. Martin de la Fuente L, et al. Virchows Arch. 2020 Jul;477(1):83-91. doi: 10.1007/s00428-020-02751-6. Epub 2020 Jan 24. Virchows Arch. 2020. PMID: 31980961 Free PMC article.

4

SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery.

Bååth M, Westbom-Fremer S, Martin de la Fuente L, Ebbesson A, Davis J, Malander S, Måsbäck A, Kannisto P, Hedenfalk I. Bååth M, et al. Among authors: martin de la fuente l. Mol Cell Oncol. 2020 Sep 5;7(6):1805094. doi: 10.1080/23723556.2020.1805094. Mol Cell Oncol. 2020. PMID: 33235906 Free PMC article.

5

Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method.

Arildsen NS, Martin de la Fuente L, Måsbäck A, Malander S, Forslund O, Kannisto P, Hedenfalk I. Arildsen NS, et al. Among authors: martin de la fuente l. Sci Rep. 2019 Oct 29;9(1):15506. doi: 10.1038/s41598-019-51697-6. Sci Rep. 2019. PMID: 31664085 Free PMC article.

6

A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.

Hüttenhain R, Choi M, Martin de la Fuente L, Oehl K, Chang CY, Zimmermann AK, Malander S, Olsson H, Surinova S, Clough T, Heinzelmann-Schwarz V, Wild PJ, Dinulescu DM, Niméus E, Vitek O, Aebersold R. Hüttenhain R, et al. Among authors: martin de la fuente l. Mol Cell Proteomics. 2019 Sep;18(9):1836-1850. doi: 10.1074/mcp.RA118.001221. Epub 2019 Jul 9. Mol Cell Proteomics. 2019. PMID: 31289117 Free PMC article.

7

[No title available]

[No authors listed] [No authors listed] PMID: 33451539

8

Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters.

Westbom-Fremer S, Tran L, Ebbesson A, Martin de la Fuente L, Jönsson JM, Kannisto P, Veerla S, Hedenfalk I. Westbom-Fremer S, et al. Among authors: martin de la fuente l. Cancer Immunol Immunother. 2025 Jan 3;74(2):56. doi: 10.1007/s00262-024-03911-2. Cancer Immunol Immunother. 2025. PMID: 39751944 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters